|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�����������崯 |
|
���� |
|
Ԥ�� |
| ��������������� | |
|
������ |
|
������ |
|
����� |
| PubMed | |
|
Article by |
|
Article by |
|
Article by |
�����������崯�IJ��̡�Ԥ���������
������, ������, �����
ɽ��ʡƤ�����Բ������о���, ����250022
�����������崯��һ������������Ƥ����,���ٴ����̡�Ԥ�����ܴ����о�����,�����������崯����ԭ�������塢���ߵ����䡢һ��������鷢���������Ƶ�����,�����ܶ��ٴ����̺�Ԥ����һ��Ӱ�졣���оʹ˷�����о���չ������������
[2] Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol, 1992, 26(4):585-589.
[3] Bernard P, Badane C, Bonnetblanc JM. Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid:a cohort analysis of 94 elderly patients. Br J Dermatol, 1997, 136 (5):694-698.
[4] Bernard P, Enginger V, Venot J, et al. Survival prognosis in pemphigoid. A cohort analysis of 78 patients. Ann Dermatol Venereol, 1995,122(11-12):751-757.
[5] Tanaka M, Hashimoto T, Dykes PJ, et al. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles. Clin Exp Dermatol, 1996, 21 (1):23-27.
[6] Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol,1998, 134 (4):465-469.
[7] Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid:low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol, 2002, 138(7):903-908.
[8] Edwards S, Wakelin SH, Wojnarowska F, et al. Bullous pemphigoid and epidermolysis bullosa acquisita:presentation, prognosis, and immunopathology in 11 children. Pediatr Dermato. l, 1998, 15 (3):184-190.
[9] Odom RB, et al. Andrews' Diseases of the Skin. 9th ed, Philadelphia:Saunders, 2000. 586-589.
[10] Cozzani E, Parodi A, Rebora A,et al. Bullous pemphigoid in Liguria:a 2-year survey. J Eur Acad Dermatol Venereol, 2001, 15 (4):317-319.
[11] Sato Y, Endo K, Ishikawa S, et al. A case of resected lung cancer associated with bullous pemphigoid. Nippon Kyobu Geka Gakkai Zasshi,1996, 44(4):524-528.
[12] Freedberg IM, et al. Fitzpatrick's Dermatology in General Medicine.5th ed, New York:McGraw-Hill, 1999. 666-671.
[13] Ramam KV. Adjuvant therapy of bullous pemphigoid with mycophenolate mofetil:old drug, new use. Singapore Med J, 2001, 42(10):482-484.
[14] Zimmermann R, Faure M, Claudy A. Prospective study of treatment of bullous pemphigoid by a class I topical corticosteroid. Ann Dermatol Venereol, 1999, 126(1):13-16.
[15] Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol, 2001, 45(6):825-835.
[16] Paul MA, Jorizzo JL, Fleischer AB Jr, et al. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol, 1994, 31 (4):620-625.
[17] Heilborn JD, Stahle-Backdahl M, Albertioni F, et al. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol, 1999, 40(5 Pt 1):741-749.
[18] Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med,2002, 346(5):321-327.